All News
Best of 2023: Our old friend, hydroxychloroquine
After an action packed weekend, RheumNow Live 2023 concluded on Sunday with a half-day session on systemic lupus erythematous and ankylosing spondylitis discussing many new medications that are revolutionizing rheumatology. Dr. Laurent Arnaud, a professor at Strasbourg University in France, however, took the time to review one of our oldest therapies: hydroxychloroquine.
Read ArticleICYMI: ACR Plenaries: Changing the Practice of Rheumatology
Over the years of navigating the annual meeting, I found the sessions with the most impact to my practice were the Plenary Sessions. During these sessions, the latest research is presented, new ideas are floated, and old myths debunked. Here are the top ACR2023 Plenary abstracts I found impactful for my practice.
Read ArticleICYMI: Maintain Vigilance for CV Risk Postpartum in Autoimmune Diseases
Pregnant women with autoimmune rheumatic diseases (ARDs) and antiphospholipid syndrome (APS) face significantly increased risks of cardiovascular events (CVEs). This increased risk is often attributed to ARDs, its medications or comorbidities associated with it.
Read ArticleICYMI: Urinary biomarkers precede loss of kidney function for lupus nephritis
In Abstract 0850, Dr. Andrea Fava from Johns Hopkins presents research on the value of urinary biomarkers as measure of intrarenal inflammation.
Read ArticleICYMI: Glucocorticoids-free zone in SLE?
For over 70 years, glucocorticoids, (GC) have been a part of standard therapy in SLE. They are classically used to not only induce remission or treat an acute flare, but also as maintenance therapy. They are a valuable 'friend' if used wisely, and can become a 'foe' if used excessively.
Read ArticleFDA Warning on CAR-T Cell Therapy
On Nov. 28, 2024, FDA issued a safety alert regarding CAR-T cell immunotherapies; noting reports of T-cell malignancies (CAR-positive lymphoma) arising in patients treated with BCMA- or CD19-directed autologous CAR T cell immunotherapies and that if there is a risk, this only applies to currently approved BCMA-directed and CD19-directed genetically modified autologous CAR T cell immunotherapies.
Read ArticleICYMI: Are Rheumatologists doing Enough for Cervical Cancer?
Should rheumatologists be counseling patients on cervical cancer prevention and screening?
Read ArticleICYMI: The Heart of Lupus
Few people are aware of the EULAR recommendations for cardiovascular risk management in SLE published in 2022. The recommendations had 4 overarching principles: increase awareness of elevated cardiovascular risk, need for regular cardiovascular screening, assess and manage modifiable risk factors, and patient education. During ACR 2023 Convergence, several abstracts were presented evaluating the prevalence of CV disease and exploring new tools to predict CV disease.
Read ArticleLinks:
Links:
Early aggressive treatment in SLE: are we there yet?
Early treatment with DMARDs has revolutionised the outcomes of patients with rheumatic arthritis. However, this concept has not been fully extrapolated to other autoimmune rheumatic diseases such as systemic lupus erythematosus.
Read ArticleJAKi and TYK2i: What to use and when?
You can see that the JAKi/TYK2i have both approved or potential seropositive and seronegative indications. There are also improvements in PsO for the class and studies in CTDs. So, it is difficult to know which to choose.
Read Article